Galderma reaches an agreement to buy ZO Skin Health, a U.S. skincare company, for $1.5 billion in cash, according to multiple reports. The deal is described as involving ZO Skin Health’s sale from Blackstone, and references also point to the Obagi family’s involvement as part of the transaction.
The outlets report that the purchase price is set at $1.5 billion and that the consideration is paid in cash. Reporting also indicates the seller is Blackstone, with the transaction framed as a significant expansion move for Galderma into the U.S. skincare market. While details beyond the purchase price—such as timing, regulatory steps, and closing conditions—may vary by source or remain unspecified in the excerpts provided, all accounts agree on the core terms.
Overall, the coverage aligns on the headline figures: Galderma as the buyer, ZO Skin Health as the target, and a $1.5 billion cash acquisition linked to Blackstone and the Obagi family.
